The Company encourages shareholders who have any concerns to call the corporate headquarters and ask to speak with Michael Senken , the Company's CFO, Bill Taylor , the Company's President & COO, or Pete Petit .
"I would encourage our shareholders to disregard the rumors and innuendo, both positive and negative, that develop from chat rooms, Twitter postings or other forms of social media," added Petit. "We have quality analysts who are currently covering MiMedx, and we expect coverage to be initiated by others in the future. It would be prudent to rely on their opinions, rather than social media posts by short sellers who have no immediately enforceable regulatory restrictions on their comments. I want to reiterate that if shareholders have concerns about things you read or hear, please contact one of our executives, who will be happy to answer your questions within regulatory guidelines."
The Company also reminded shareholders that Messrs. Petit, Taylor and Senken will be presenting this week at the Canaccord Genuity Musculoskeletal Conference in Chicago. The MiMedx executives will be presenting on Tuesday, March 19th, at 3:20 p.m. Central Time/4:20 p.m. Eastern Time, and a webcast of this presentation will be available on the Company's website, www.mimedx.com.
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, an
|SOURCE MiMedx, Inc.|
Copyright©2012 PR Newswire.
All rights reserved